These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 11419183

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
    Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V.
    Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
    [Abstract] [Full Text] [Related]

  • 5. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
    Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R.
    Blood; 1997 Sep 15; 90(6):2188-95. PubMed ID: 9310469
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 2004 Apr 15; 10(8):2868-78. PubMed ID: 15102696
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA.
    Cancer Biother Radiopharm; 1999 Aug 15; 14(4):241-50. PubMed ID: 10850310
    [Abstract] [Full Text] [Related]

  • 15. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
    Tobinai K.
    Cancer Chemother Pharmacol; 2001 Aug 15; 48 Suppl 1():S85-90. PubMed ID: 11587374
    [Abstract] [Full Text] [Related]

  • 16. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
    Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-López AJ.
    J Clin Oncol; 1999 Dec 15; 17(12):3793-803. PubMed ID: 10577851
    [Abstract] [Full Text] [Related]

  • 17. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma.
    Scott SD.
    Cancer Pract; 1998 Dec 15; 6(3):195-7. PubMed ID: 9652253
    [Abstract] [Full Text] [Related]

  • 18. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
    Kriachok IA, Filonenko KS, Gubareva GO, Tytorenko IB, Novosad OI, Kadnikova TV, Aleksik OM, Martynchyk AV, Kushchevyĭ ÉV, Pastushenko IaV, Kutsenko LB.
    Lik Sprava; 2011 Dec 15; (1-2):117-21. PubMed ID: 21954645
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
    Pijuan L, Vicioso L, Bellosillo B, Ferrer MD, Baró T, Pedro C, Lloreta-Trull J, Munné A, Serrano S.
    Am J Surg Pathol; 2005 Oct 15; 29(10):1399-403. PubMed ID: 16160485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.